FAS and ovarian cancer: To evaluate if a Fas-4-1BB IFP might improve activity against human ovarian cancer, three unique donors were transduced to express a human TCR specific for MSLN peptide 530–538 (TCR530) with or without a truncated Fas or a Fas-4-1BB IFP.